# Papillomavirus Infections FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/papillomavirus-infections

> 12 upcoming FDA catalysts in papillomavirus Infections: 9vhpv vaccine (MRK) on Jan to Apr 2027 (topline data readout); 9vhpv vaccine (MRK) on January 2027 (primary completion); V503 (MRK) on Dec 2027 to Mar 2028 (topline data readout); V503 (MRK) on December 2027 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan to Apr 2027 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04199689)) |
| January 2027 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04199689)) |
| Dec 2027 to Mar 2028 | [V503 topline data readout](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT07785843 (A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07785843)) |
| December 2027 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT07785843 (A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07785843)) |
| Mar to Jun 2028 | [V503 topline data readout](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT03998254 (Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998254)) |
| March 2028 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT03998254 (Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998254)) |
| May to Aug 2029 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05285826)) |
| May 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05285826)) |
| Aug to Nov 2029 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450705)) |
| August 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450705)) |
| Oct 2029 to Jan 2030 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708041)) |
| October 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708041)) |

## Drugs

- [9vhpv vaccine](https://sec-api.dev/pdufa/9vhpv-vaccine) (MRK)
- [V503](https://sec-api.dev/pdufa/v503) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/papillomavirus-infections.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Papillomavirus Infections FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/papillomavirus-infections

```bibtex
@misc{secapidev_indications_papillomavirus_infections_20261116,
  title        = {Papillomavirus Infections FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/papillomavirus-infections}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_papillomavirus_infections_20261116","title":"Papillomavirus Infections FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/papillomavirus-infections","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
